

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS PS O Box 1450 Alexandris, Virginia 22313-1450 www upple gov

APPLICATION NO.	FILING	G DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/574,992	01/13	2/2007	Thomas A. Miller	21824YP	3515
210 MERCK	7590 06/25/2010		EXAM	IINER	
P O BOX 2000				DENTZ, BERNARD I	
RAHWAY, NJ 07065-0907				ART UNIT	PAPER NUMBER
				1625	•
				MAIL DATE	DELIVERY MODE
				06/25/2010	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Application No. Applicant(s) 10/574.992 MILLER ET AL. Office Action Summary Examiner Art Unit Bernard Dentz -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS. WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status 1) Responsive to communication(s) filed on 2a) ☐ This action is FINAL. 2b) This action is non-final. 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. Disposition of Claims 4) Claim(s) 1-24.30-33.36.37 and 41 is/are pending in the application. 4a) Of the above claim(s) 16-23, 31-33,36,37 and 41 in toto and 24in part, is/are withdrawn from consideration. 5) Claim(s) _____ is/are allowed. 6) Claim(s) 1-3.24 and 30 is/are rejected. 7) Claim(s) 4-15 is/are objected to. 8) Claim(s) _____ are subject to restriction and/or election requirement. Application Papers 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are; a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. Priority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. Attachment(s)

1) Notice of References Cited (PTO-892)

Notice of Draftsperson's Patent Drawing Review (PTO-948)
Information Disclosure Statement(s) (PTO/SB/08)

Paper No(s)/Mail Date See Continuation Sheet.

Interview Summary (PTO-413)
Paper No(s)/Mail Date.

6) Other:

5) Notice of Informal Patent Application

 $Continuation \ of \ Attachment(s)\ 3).\ Information \ Disclosure\ Statement(s)\ (PTO/SB/08),\ Paper\ No(s)/Mail\ Date: 5-9-07,5-19\ and 8-25-09,4-15-10,.$

Application/Control Number: 10/574,992

Art Unit: 1625

Applicants have elected to prosecute the compounds and their pharmaceutical compositions.

Restriction is required as follows:

alkyl or phenyl as values of A

- Claims 1-15, 24 and 30, the last 2 in part, drawn to the above where the benzothiophene compounds have a value of A containing a functional group
 Claims 1,2 and 30 drawn to the above where the benzothiophene compounds have
- III. Claims 16-23 and 24, the last in part, drawn to Thiophene compounds having a value of A containing a functional group
- IV. Claims 16-19 drawn to thiophene compounds where A is alkyl or phenylApplicants by electing a compound within Gp. I have constructively elected said group.

Pharmaceutical method claims 31-33, 36,37 and 41 are withdrawn from consideration. Note that some of the benzothiophene compounds of "list of species" claim 24 are not within the scope of claim 1. For example see compounds 6-8 on p. 24.

Applicants must delete <u>all</u> of the compounds not falling within the generic claim. They are considered to be non-elected.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims1-3, 24 and 30 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. IN claim 1 the heteroalkyl and sulfonyl are not

Application/Control Number: 10/574,992

Art Unit: 1625

readily understandable. IN claims 1 and 2 only one of the pairs of R's are present in a single compound. Therefore "one or more" must be canceled in the third line under the structural formulae.

Claim 24 contains non-elected material which must be canceled.

Claims 4-15 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Bernard Dentz whose telephone number is 571-272-0683. The examiner can normally be reached on Mon-Fri from 8:30 to 4.00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Janet Andres, can be reached on 571 272-0867. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://portal.uspto.gov/external/portal. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Application/Control Number: 10/574,992

Page 4

Art Unit: 1625

Primary Examiner, Art Unit 1625